| Scancell announces CFO transition | 02-Apr-2026 | 07:00 | RNS |
| Half-year Financial Report | 29-Jan-2026 | 07:00 | RNS |
| FDA clearance of IND application for iSCIB1+ | 26-Jan-2026 | 07:00 | RNS |
| Notice of Results | 22-Jan-2026 | 07:00 | RNS |
| Continued improvement in PFS with iSCIB1+ | 09-Dec-2025 | 07:00 | RNS |
| Research Update | 07-Nov-2025 | 07:00 | RNS |
| Notice of AGM | 03-Oct-2025 | 07:00 | RNS |
| Director Dealing | 16-Sep-2025 | 07:00 | RNS |
| Final Results | 11-Sep-2025 | 07:00 | RNS |
| Notice of Results | 04-Sep-2025 | 07:00 | RNS |
| Director Dealing | 08-Aug-2025 | 12:31 | RNS |
| Director/PDMR Shareholding | 04-Aug-2025 | 10:23 | RNS |
| Strong Phase 2 data on iSCIB1+ in Melanoma | 22-Jul-2025 | 07:00 | RNS |
| Share Option Exercise | 16-Jul-2025 | 07:00 | RNS |
| Scancell initiates new arm in SCOPE Phase 2 study | 25-Jun-2025 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 12.83p |
| Change Today | -0.42p |
| % Change | -3.14 % |
| 52 Week High | 13.83p |
| 52 Week Low | 8.54p |
| Volume | 462,486 |
| Shares Issued | 1,037.78m |
| Market Cap | £133.18m |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 1 |
| Buy | 2 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 15:52 | 50,201 @ 13.15p |
| 15:50 | 15,156 @ 13.15p |
| 15:37 | 885 @ 12.50p |
| 14:50 | 38,324 @ 13.07p |
| 14:41 | 1,000 @ 13.07p |
| CFO | Sath Nirmalananthan |
| CEO | Phil L'Huillier |
You are here: research